Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Songyi Park, Sang-A Kim, Ji Yun Lee, Ja Min Byun, Jeong-Ok Lee, Youngil Koh, Junshik Hong, Junglim Lee, Soo-Mee Bang, Inho Kim, Sung-Soo Yoon, Dongyeop Shin

Blood (2024) 144 (Supplement 1): 5944.

https://doi.org/10.1182/blood-2024-202293

Published: 2024

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Journal Articles

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Seok Jin Kim, SangEun Yoon, Ji Hyun Lee, Jeong-Ok Lee, Seong Hyun Jeong, Sung-Nam Lim, Ho-Jin Shin, Duck Hwan Yang, Won Seog Kim

Blood (2024) 144 (Supplement 1): 1683.

https://doi.org/10.1182/blood-2024-205026

Published: 2024

Journal Articles

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2024-200397

Published: 2024

Journal Articles

Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)

Hawk Kim, Jae-Sook Ahn, Sung-Hyun Kim, Ho-Young Yhim, Sung-Nam Lim, Yoo Jin Lee, Jeong-Ok Lee, Eun-Ji Choi, Je-Hwan Lee

Blood (2024) 144 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2024-201404

Published: 2024

Journal Articles

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Blood (2024) 144 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2024-207033

Published: 2024

Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2023) 142 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2023-185606

Published: 2023

Journal Articles

Real-World Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis at a Single Center

Sang-A Kim, Ji Yun Lee, Soo-Mee Bang, Jeong-Ok Lee

Blood (2023) 142 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2023-188410

Published: 2023

Journal Articles

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Bong-Seog Kim, Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Tae Min Kim, Eunyoung Lee, Jeong-Ok Lee, Deok-Hwan Yang, Won-Sik Lee

Blood (2023) 142 (Supplement 1): 1701.

https://doi.org/10.1182/blood-2023-173010

Published: 2023

Journal Articles

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Naval Daver, Kyoo Hyung Lee, Yunsuk Choi, Brian A. Jonas, Martha Arellano, Paul B. Koller, Chul W. Jung, Sang Kyun Sohn, Amir T. Fathi, Jeong-Ok Lee, Sung-Soo Yoon, Justin M. Watts, Pankit Vachhani, Ho-Jin Shin, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar

Blood (2023) 142 (Supplement 1): 162.

https://doi.org/10.1182/blood-2023-182296

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M. Stone, Alan Saven, Jessica K. Altman, Michael R. Grever, Kanti R. Rai, Madhulika Shukla, Shreya Vemuri, Skye Montoya, Justin Taylor, Omar Abdel-Wahab, Martin S. Tallman, Jae H. Park

Blood (2022) 140 (25): 2663–2671.

https://doi.org/10.1182/blood.2022016183

Published: 2022

Journal Articles

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Naval Daver, Kyoo Hyung Lee, Brian A. Jonas, Martha L. Arellano, Chul W. Jung, Sang Kyun Sohn, Sung-Soo Yoon, Jeong-Ok Lee, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6197–6199.

https://doi.org/10.1182/blood-2022-167972

Published: 2022

Journal Articles

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 9498–9500.

https://doi.org/10.1182/blood-2022-165716

Published: 2022

Journal Articles

Preliminary Result of a Pilot Study of Apixaban in the Treatment of Splanchnic Vein Thrombosis

Sang-A Kim, Ji Yun Lee, Jeong-Ok Lee, Soo-Mee Bang

Blood (2022) 140 (Supplement 1): 5678–5679.

https://doi.org/10.1182/blood-2022-168446

Published: 2022

Journal Articles

Incidence of Skeletal-Related Events Among Multiple Myeloma Patients: A Nationwide Population-Based Cohort Study

Ji Yun Lee, Ju Hyun Lee, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Jong-Seok Lee, Soo-Mee Bang, Eun Hee Jung, Minsu Kang

Blood (2022) 140 (Supplement 1): 12570.

https://doi.org/10.1182/blood-2022-168747

Published: 2022

Journal Articles

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Joseph Clarey, Jeejin Im, Suntae Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, Jeong Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2022) 140 (Supplement 1): 3365–3366.

https://doi.org/10.1182/blood-2022-165000

Published: 2022

Journal Articles

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Anish Puliyayil, Joseph Clarey, Jeejin Im, Ky-Youb Nam, Kyu-Tae Kim, June H-J. Han, Jeong-Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2021) 138 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2021-149395

Published: 2021

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

Journal Articles

Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis

Jeong-Ok Lee, MD, Dong-Wook Kim, MD PhD, Elisabetta Abruzzese, MD, Jane Apperley, MB ChB MD, Louise Caldwell, BSc, Michael J. Mauro, MD

Blood (2018) 132 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2018-99-119615

Published: 2018

NARROW

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Real-World Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis at a Single Center

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Preliminary Result of a Pilot Study of Apixaban in the Treatment of Splanchnic Vein Thrombosis

Incidence of Skeletal-Related Events Among Multiple Myeloma Patients: A Nationwide Population-Based Cohort Study

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only